SCHEMBL7138368

SCHEMBL7138368

Fc1ccc(-c2ncc(-c3cccc(CNC4CC4)c3)[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.47
CNR1 P21554 3/20 0.47
KCNH2 Q12809 1/20 0.46
BACE1 P56817 1/20 0.45
HPGDS O60760 2/20 0.44
VCP P55072 1/20 0.44
SCN2A Q99250 3/20 0.43
MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8190593 0.97 KCNH2 (0.48) CNR2CNR1KCNH2BACE1HPGDS
SCHEMBL7143478 0.96 KCNH2 (0.49) CNR2CNR1KCNH2BACE1HPGDS
SCHEMBL8119014 0.95 KCNH2 (0.51) CNR2CNR1KCNH2BACE1HPGDS
SCHEMBL7142302 0.91 SCN2A (0.52) CNR2CNR1HPGDSVCPSCN2A
SCHEMBL8118669 0.90 KCNH2 (0.46) CNR2CNR1KCNH2BACE1HPGDS
SCHEMBL7139526 0.86 SCN2A (0.50) CNR2CNR1KCNH2HPGDSVCP
SCHEMBL8117997 0.86 SCN2A (0.50) CNR2CNR1HPGDSVCPSCN2A
SCHEMBL7142281 0.81 SCN2A (0.47) CNR2CNR1BACE1HPGDSSCN2A
SCHEMBL7179734 0.81 BACE1 (0.47) CNR2CNR1BACE1HPGDSSCN2A
SCHEMBL7143623 0.81 BACE1 (0.46) CNR2CNR1BACE1HPGDSSCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed